Sandbox:Sara: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) No edit summary |
Sara Mohsin (talk | contribs) No edit summary |
||
| Line 7: | Line 7: | ||
*Treatment is primarily [[surgical]], with [[chemotherapy]] and [[radiation therapy]] sometimes being used. | *Treatment is primarily [[surgical]], with [[chemotherapy]] and [[radiation therapy]] sometimes being used. | ||
*There is clinical evidence that [[imatinib]], which inhibits PDGFB, may be effective for tumors positive for the t(17;22) translocation. | *There is clinical evidence that [[imatinib]], which inhibits PDGFB, may be effective for tumors positive for the t(17;22) translocation. | ||
==Reference== | |||
{{Reflist|2}} | |||
Revision as of 16:36, 16 August 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
- Treatment includes:[1][2][3][4][5][6]
- Imatinib-STI571 (tyrosine kinase inhibitor) therapy (may be effective in CD117- tumors) is the gold standard treatment of recurrent or inoperable tumor
- Excisional sugery including the removal of subcutaneous fat (i.e. wide local excision with 2 - 3 cm margins) alongwith 3-dimensional histologic evaluation of margins is necessarily recommended in order to prevent the tumor recurrence
- Treatment is primarily surgical, with chemotherapy and radiation therapy sometimes being used.
- There is clinical evidence that imatinib, which inhibits PDGFB, may be effective for tumors positive for the t(17;22) translocation.
Reference
- ↑ Huis In 't Veld EA, van Houdt WJ (2019). "Reply to Follow-up after treatment of dermatofibrosarcoma protuberans". Cancer. doi:10.1002/cncr.32341. PMID 31251395.
- ↑ Loss L, Zeitouni NC (2005). "Management of scalp dermatofibrosarcoma protuberans". Dermatol Surg. 31 (11 Pt 1): 1428–33. PMID 16416612.
- ↑ Dawes KW, Hanke CW (1996). "Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins". Dermatol Surg. 22 (6): 530–4. PMID 8646467.
- ↑ Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM; et al. (2000). "Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution". Cancer. 88 (12): 2711–20. PMID 10870053.
- ↑ DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK (2004). "Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution". Cancer. 100 (5): 1008–16. doi:10.1002/cncr.20051. PMID 14983497.
- ↑ Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB (2004). "Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature". Cancer. 101 (1): 28–38. doi:10.1002/cncr.20316. PMID 15221986.